Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats

Arthritis and Rheumatism

Volumn 56, Issue 4, 2007, Pages 1187-1197

  Fischetti, Fabio ^a   Durigutto, Paolo ^a   Macor, Paolo ^a   Marzari, Roberto ^a   Carretta, Renzo ^a   Tedesco, Francesco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C9; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TERMINAL COMPLEMENT COMPLEX; TS A 12 22; TS A 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; JOINT SWELLING; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; WISTAR RAT;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; COMPLEMENT C5A; COMPLEMENT C6; COMPLEMENT INACTIVATOR PROTEINS; GENE SILENCING; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INJECTIONS, INTRA-ARTICULAR; MALE; RATS; RATS, MUTANT STRAINS; RATS, WISTAR; STIFLE; SYNOVIAL FLUID; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247197849     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22492     Document Type: Article

References (56)

1. Morgan BP. The complement system: an overview [review]. Methods Mol Biol 2000;150:1-13.
2. Hietala MA, Nandakumar KS, Persson L, Fahlen S, Holmdahl R, Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol 2004;34:1208-16.
3. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum 2002;46:934-45.
4. Takemura S, Ueda M, Tagami H, Kato H, Yoshikawa T, Kawakami N, et al. Relation of clinical activity of rheumatoid arthritis to immune complexes, complement components and anti-immunoglobulins. Rheumatol Int 1984;4:159-63.
5. Makinde VA, Senaldi G, Jawad AS, Berry H, Vergani D. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis 1989;48:302-6.
6. Petersen NE, Elmgreen J, Teisner B, Svehag SE. Activation of classical pathway complement in chronic inflammation: elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease. Acta Med Scand 1988;223:557-60.
7. Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001;44:997-1002.
8. Wouters D, Voskuyl AE, Molenaar ET, Dijkmans BA, Hack CE. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Arthritis Rheum 2006;54:1143-50.
9. Ruddy S, Colten HR. Rheumatoid arthritis: biosynthesis of complement proteins by synovial tissues. N Engl J Med 1974;290:1284-8.
10. Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum 1986;29:715-21.
11. Swaak AJ, van Rooyen A, Planten O, Han H, Hattink O, Hack E. An analysis of the levels of complement components in the synovial fluid in rheumatic diseases. Clin Rheumatol 1987;6:350-7.
12. Doherty M, Richards N, Hornby J, Powell R. Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy. Ann Rheum Dis 1988;47:190-7.
13. Olmez U, Garred P, Mollnes TE, Harboe M, Berntzen HB, Munthe E. C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis. Scand J Rheumatol 1991;20:183-9.
14. Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991;34:1094-105.
15. Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1531-7.
16. Corvetta A, Pomponio G, Rinaldi N, Luchetti MM, Di Loreto C, Stramazzotti D. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin Exp Rheumatol 1992;10:433-8.
17. Shingu M, Watanabe Y, Tomooka K, Yoshioka K, Ohtsuka E, Nobunaga M. Complement degradation products in rheumatoid arthritis synovial fluid. Br J Rheumatol 1994;33:299-300.
18. Hogasen K, Mollnes TE, Harboe M, Gotze O, Hammer HB, Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995;22:24-8.
19. Konttinen YT, Ceponis A, Meri S, Vuorikoski A, Kortekangas P, Sorsa T, et al. Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis 1996;55:888-94.
20. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 1995;92:8955-9.
21. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol 1997;110:45-52.
22. Mizuno M, Nishikawa K, Goodfellow RM, Piddlesden SJ, Morgan BP, Matsuo S. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum 1997;40:527-33.
23. Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999;36:905-14.
24. Mizuno M, Nishikawa K, Morgan BP, Matsuo S. Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59. Clin Exp Immunol 2000;119:368-75.
25. Linton SM, Williams AS, Dodd I, Smith R, Williams BD, Morgan BP. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum 2000;43:2590-7.
26. Goodfellow RM, Williams AS, Levin JL, Williams BD, Morgan BP. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis. Clin Exp Immunol 2000;119:210-6.
27. Mizuno M, Nishikawa K, Spiller OB, Morgan BP, Okada N, Okada H, et al. Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis Rheum 2001;44:2425-34.
28. Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, et al. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol 2002;32:2773-82.
29. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, et al. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002;46:2476-85.
30. Andersson SE, Lexmuller K, Ekstrom GM. Physiological characterization of mBSA antigen induced arthritis in the rat. I. Vascular leakiness and pannus growth. J Rheumatol 1998;25:1772-7.
31. Andersson SE, Johansson A, Lexmuller K, Ekstrom GM. Physiological characterization of mBSA antigen induced arthritis in the rat. II. Joint blood flow, glucose metabolism, and cell proliferation. J Rheumatol 1998;25:1778-84.
32. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, et al. Animal models of arthritis: relevance to human disease. Toxicol Pathol 1999;27:134-42.
33. Wang Y, Kristan J, Hao L, Lenkoski CS, Shen Y, Matis LA. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol 2000;164:4340-7.
34. Banda NK, Kraus D, Vondracek A, Huynh LH, Bendele A, Holers VM, et al. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum 2002;46:3065-75.
35. Williams AS, Mizuno M, Richards PJ, Holt DS, Morgan BP. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum 2004;50:3035-44.
36. Grant EP, Picarella D, Burwell T, Delaney T, Croci A, Avitahl N, et al. Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis. J Exp Med 2002;196:1461-71.
37. Leenaerts PL, Stad RK, Hall BM, van Damme BJ, Vanrenterghem Y, Daha MR. Hereditary C6 deficiency in a strain of PVG/c rats. Clin Exp Immunol 1994;97:478-82.
38. Oppermann M, Schulze M, Gotze O. A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm 1991;8:13-24.
39. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997;185:1619-27.
40. Van Lent PL, van den Bersselaar LA, van den Hoek AE, van de Loo AA, van den Berg WB. Cationic immune complex arthritis in mice - a new model: synergistic effect of complement and interleukin-1. Am J Pathol 1992;140:1451-61.
41. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically dependent on innate immune system players. Immunity 2002;16:157-68.
42. Lee H, Zahra D, Vogelzang A, Newton R, Thatcher J, Quan A, et al. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat Biotechnol 2006;24:1279-84.
43. Tramontini NL, Kuipers PJ, Huber CM, Murphy K, Naylor KB, Broady AJ, et al. Modulation of leukocyte recruitment and IL-8 expression by the membrane attack complex of complement (C5b-9) in a rabbit model of antigen-induced arthritis. Inflammation 2002;26:311-9.
44. Von Kempis J, Torbohm I, Schonermark M, Jahn B, Seitz M, Hansch GM. Effect of the late complement components C5b-9 and of platelet-derived growth factor on the prostaglandin release of human synovial fibroblast-like cells. Int Arch Allergy Appl Immunol 1989;90:248-55.
45. Daniels RH, Houston WA, Petersen MM, Williams JD, Williams BD, Morgan BP. Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack. Immunology 1990;69:237-42.
46. Niculescu F, Rus H. Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res 2001;24:191-9.
47. Dobrina A, Pausa M, Fischetti F, Bulla R, Vecile E, Ferrero E, et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 2002;99:185-92.
48. Casarsa C, De Luigi A, Pausa M, De Simoni MG, Tedesco F. Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain. Eur J Immunol 2003;33:1260-70.
49. De Benedetti F, Pignatti P, Gerloni V, Massa M, Sartirana P, Caporali R, et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997;24:1403-9.
50. Lettesjo H, Nordstrom E, Strom H, Nilsson B, Glinghammar B, Dahlstedt L, et al. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol 1998;48:286-92.
51. Manicourt DH, Poilvache P, van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000;43:281-8.
52. Saxena N, Aggarwal A, Misra R. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis. J Rheumatol 2005;32:1349-53.
53. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004;22:39-53.
54. Schwartzman S, Fleischmann R, Morgan GJ Jr. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther 2004;6 Suppl 2:S3-11.
55. Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis [review]. Pharmacogenomics 2005;6:481-90.
56. Symmons DP, Silman AJ. The world of biologics [review]. Lupus 2006;15:122-6.